Amicus Therapeutics Non-GAAP EPS of $0.18 beats by $0.06, revenue of $169.06M beats by $3.35M

4 hours ago 1

Amicus Therapeutics press release (FOLD): Q3 Non-GAAP EPS of $0.18 beats by $0.06.
Revenue of $169.06M (+19.5% Y/Y) beats by $3.35M.
Amicus reiterates its financial guidance for 2025, as follows:

Total Revenue Growth¹ 15% to 22%

Galafold Revenue Growth

Total Revenue Growth¹	15% to 22%
Galafold Revenue Growth